Developing expert consensus for the use of hedgehog inhibitors in basal cell nevus syndrome

Arch Dermatol Res. 2024 Jul 5;316(7):453. doi: 10.1007/s00403-024-03157-z.

¹ Center for Dermatology, Rutgers Robert Wood Johnson Medical School, Somerset, NJ, USA. [email protected].
² Department of Dermatology, University of Illinois Chicago, Chicago, IL, USA.
³ Department of Dermatology, Columbia University, New York, NY, USA.
⁴ Department of Dermatology, Section of Dermatologic Surgery, Yale University, New Haven, CT, USA.
⁵ Department of Dermatology, Stanford University, Redwood City, CA, USA.
⁶ Department of Dermatology, Duke University, Durham, NC, USA.
⁷ Atrium Health Levine Cancer Institute, Wake Forest School of Medicine, Charlotte, NC, USA.
⁸ Moffitt Cancer Center, Tampa, FL, USA.
⁹ Patient representative, Texas, USA.
¹⁰ Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
¹¹ Department of Dermatology, Cleveland Clinic, Cleveland, OH, USA.

No abstract available

Keywords: Basal cell carcinoma; Basal cell nevus syndrome; Gorlin syndrome; Hedgehog inhibitors; Multidisciplinary care.

Publication types